p53 and Ras mutations in cancer and experimental carcinogenesis

Current Cancer Research

Volumn 6, Issue , 2011, Pages 401-422

  Abedin, Zahidur ^b   Sen, Sushmita ^b   Morocco, Elise ^b   Field, Jeffrey ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

4 (METHYLNITROSAMINO) 1 (3 PYRIDYL) 1 BUTANONE; AFLATOXIN; CIGARETTE SMOKE; GUANOSINE TRIPHOSPHATASE; K RAS PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; POLYCYCLIC AROMATIC HYDROCARBON; PROTEIN P53; RAF PROTEIN; RAS PROTEIN;

3' UNTRANSLATED REGION; 5' UNTRANSLATED REGION; AMINO ACID SUBSTITUTION; APOPTOSIS; ARTICLE; BLADDER CANCER; BREAST CANCER; CARCINOGENESIS; CELL CYCLE ARREST; CELL DIFFERENTIATION; CELL GROWTH; CELL MOTILITY; CELL PROLIFERATION; CHEMICAL STRUCTURE; CODON; COMBUSTION; DNA BINDING; DNA DAMAGE; DNA REPAIR; DNA REPLICATION; DNA SEQUENCE; ENZYME ACTIVITY; ENZYME INACTIVATION; GENE FREQUENCY; GENE MAPPING; GENE MUTATION; GENETIC REGULATION; GENETIC SELECTION; GENETIC SUSCEPTIBILITY; HEPATITIS B; HUMAN; IN VIVO STUDY; LIVER CANCER; LUNG CANCER; MOLECULAR EPIDEMIOLOGY; MOUTH CANCER; MUTAGENESIS; NONHUMAN; ONCOGENE; ONCOGENE H RAS; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; SMOKING; STOP CODON; TUMOR SUPPRESSOR GENE;

EID: 84870720966     PISSN: 09400745     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-61737-995-6_18     Document Type: Article

References (82)

1. Adorno, M., Cordenonsi, M., et al. (2009). A Mutant-p53/Smad complex opposes p63 to empower TGFbeta-induced metastasis. Cell 137: 87-98.
2. Arakawa, H., Wu, F., et al. (2006). Sequence specificity of Cr(III)-DNA adduct formation in the p53 gene: NGG sequences are preferential adduct-forming sites. Carcinogenesis 27: 639-45.
3. Balmain, A. and Pragnell, I.B. (1983). Mouse skin carcinomas induced in vivo by chemical carcinogens have a transforming Harvey-ras oncogene. Nature 303: 72-4.
4. Balmain, A., Ramsden, M., et al. (1984). Activation of the mouse cellular Harvey-ras gene in chemically induced benign skin papillomas. Nature 307: 658-60.
5. Barbacid, M. (1987). ras Genes. Annu Rev Biochem 56: 779-827.
6. Bizub, D., Wood, A.W., et al. (1986). Mutagenesis of the Ha-ras oncogene in mouse skin tumors induced by polycyclic aromatic hydrocarbons. Proc Natl Acad Sci USA 83: 6048-52.
7. Bos, J.L. (1989). ras oncogenes in human cancer: a review. Cancer Res 49: 4682-4689.
8. Bos, J.L., Fearon, E.R., et al. (1987). Prevalence of ras gene mutations in human colorectal cancers. Nature 327: 293-7.
9. Brachmann, R.K., Vidal, M., et al. (1996). Dominant-negative p53 mutations selected in yeast hit cancer hot spots. Proc Natl Acad Sci USA 93: 4091-4095.
10. Brown, K., Buchmann, A., et al. (1990). Carcinogen-induced mutations in the mouse c-Ha-ras gene provide evidence of multiple pathways for tumor progression. Proc Natl Acad Sci USA 87: 538-42.
11. Buchmann, A., Bauer-Hofmann, R., et al. (1991). Mutational activation of the c-Ha-ras gene in liver tumors of different rodent strains: correlation with susceptibility to hepatocarcinogenesis. Proc Natl Acad Sci USA 88: 911-5.
12. Campomenosi, P., Monti, P., et al. (2001). p53 mutants can often transactivate promoters containing a p21 but not Bax or PIG3 responsive elements. Oncogene 20: 3573-9.
13. Cardiff, R.D., Gumerlock, P.H., et al. (1988). c-H-ras-1 expression in 7,12-dimethyl benzanthraceneinduced Balb/c mouse mammary hyperplasias and their tumors. Oncogene 3: 205-13.
14. Colicelli, J. (2004). Human RAS superfamily proteins and related GTPases. Sci STKE 2004: RE13.
15. Conney, A.H. (1982). Induction of microsomal enzymes by foreign chemicals and carcinogenesis by polycyclic aromatic hydrocarbons. G.H.A. Clowes Memorial Lecture. Cancer Res 42: 4875-917.
16. Denissenko, M.F., Pao, A., et al. (1996). Preferential formation of benzo[a]pyrene adducts at lung cancer mutation hotspots in P53. Science 274: 430-2.
17. Denissenko, M.F., Koudriakova, T.B., et al. (1998a). The p53 codon 249 mutational hotspot in hepatocellular carcinoma is not related to selective formation or persistence of aflatoxin B1 adducts. Oncogene 17: 3007-14.
18. Denissenko, M.F., Pao, A., et al. (1998b). Slow repair of bulky DNA adducts along the nontranscribed strand of the human p53 gene may explain the strand bias of transversion mutations in cancers. Oncogene 16: 1241-7.
19. Diamond, L.E., Guerrero, I., et al. (1988). Concomitant K-and N-ras gene point mutations in clonal murine lymphoma. Mol Cell Biol 8: 2233-6.
20. Feng, Z., Hu, W., et al. (2002). Preferential DNA damage and poor repair determine ras gene mutational hotspot in human cancer. J Natl Cancer Inst 94: 1527-36.
21. Feng, Z., Hu, W., et al. (2003). Chromium(VI) exposure enhances polycyclic aromatic hydrocarbon-DNA binding at the p53 gene in human lung cells. Carcinogenesis 24: 771-8.
22. Feng, Z., Hu, W., et al. (2006). Acrolein is a major cigarette-related lung cancer agent: preferential binding at p53 mutational hotspots and inhibition of DNA repair. Proc Natl Acad Sci USA 103: 15404-9.
23. Flaman, J.M., Frebourg, T., et al. (1995). A simple p53 functional assay for screening cell lines, blood, and tumors. Proc Natl Acad Sci USA 92: 3963-7.
24. Gelboin, H.V. (1980). Benzo[a]pyrene metabolism, activation and carcinogenesis: role and regulation of mixed function oxidases and related enzymes. Physiol Rev 60: 1107-66.
25. Groopman, J.D. and Kensler, T.W. (2005). Role of metabolism and viruses in aflatoxin-induced liver cancer. Toxicol Appl Pharmacol 206: 131-7.
26. Groopman, J.D., Johnson, D., et al. (2005). Aflatoxin and hepatitis B virus biomarkers: a paradigm for complex environmental exposures and cancer risk. Cancer Biomark 1: 5-14.
27. Guerrero, I. and Pellicer, A. (1987). Mutational activation of oncogenes in animal model systems of carcinogenesis. Mutat Res 185: 293-308.
28. Guerrero, I., Calzada, P., et al. (1984). A molecular approach to leukemogenesis: mouse lymphomas contain an activated c-ras oncogene. Proc Natl Acad Sci USA 81: 202-5.
29. Guerrero, I., Villasante, A., et al. (1985). Loss of the normal N-ras allele in a mouse thymic lymphoma induced by a chemical carcinogen. Proc Natl Acad Sci U S A 82: 7810-4.
30. Hainaut, P. and Pfeifer, G.P. (2001). Patterns of p53 G-->T transversions in lung cancers reflect the primary mutagenic signature of DNA-damage by tobacco smoke. Carcinogenesis 22: 367-74.
31. Harvey, J.J. (1964). An unidentified virus which causes the rapid production of tumours in mice. Nature 204: 1104-5.
32. Hecht, S.S. (1998). Biochemistry, biology, and carcinogenicity of tobacco-specific N-nitrosamines. Chem Res Toxicol 11: 559-603.
33. Hecht, S.S. (1999). Tobacco smoke carcinogens and lung cancer. J Natl Cancer Inst 91: 1194-210.
34. Hernandez-Boussard, T., Rodriguez-Tome, P., et al. (1999). IARC p53 mutaion database: a relational database to compile and analyze p53 mutations in human tumors and cell lines. International Agency for research in cancer. Hum Mutat 14: 1-8.
35. Hoeijmakers, J.H.J. (2001). Genome maintenance mechanisms for preventing cancer. Nature 411: 366-74.
36. Hollstein, M., Sidransky, D., et al. (1991). p53 mutations in human cancers. Science 253: 49-53.
37. Hsu, I.C., Metcalf, R.A., et al. (1991). Mutational hotspot in the p53 gene in human hepatocellular carcinomas. Nature 350: 427-8.
38. Ishioka, C., Frebourg, T., et al. (1993). Screening patients for heterozygous p53 mutations using a functional assay in yeast. Nat Genet 5: 124-9.
39. Jeffrey, A.M., Jennette, K.W., et al. (1976). Benzo[a]pyrene-nucleic acid derivative found in vivo: structure of a benzo[a]pyrene-tetrahydrodiol epoxide-guanosine adduct. J Am Chem Soc 98: 5714-5.
40. Jennette, K.W., Jeffery, A.M., et al. (1977). Nucleoside adducts from the in vitro reaction of benzo[a]pyrene-7,8-dihydrodiol-9,10-oxide or benzo[a]pyrene-4,5-oxide with nucleic acids. Biochemistry 16: 932-8.
41. Kato, S., Han, S.Y., et al. (2003). Understanding the function-structure and function-mutation relationships of p53 tumor suppressor protein by high-resolution missense mutation analysis. Proc Natl Acad Sci USA 100: 8424-9.
42. Kirsten, W.H. and Mayer, L.A. (1967). Morphologic responses to a murine erythroblastosis virus. J Natl Cancer Inst 39: 311-35.
43. Koreeda, M., Moore, P.D., et al. (1978). Binding of benzo[a]pyrene-7,8-diol-9,10-epoxides to DNA, RNA and protein of mouse skin occurs with high stereoselectivity. Science 199: 778-81.
44. Mace, K., Aguilar, F., et al. (1997). Aflatoxin B1-induced DNA adduct formation and p53 mutations in CYP450-expressing human liver cell lines. Carcinogenesis 18: 1291-7.
45. Mangues, R. and Pellicer, A. (1992). ras activation in experimental carcinogenesis. Semin Cancer Biol 3: 229-39.
46. Marshall, C.J., Vousden, K.H., et al. (1984). Activation of c-Ha-ras-1 proto-oncogene by in vitro modification with a chemical carcinogen, benzo(a)pyrene diol-epoxide. Nature 310: 586-9.
47. Miyamoto, S., Sukumar, S., et al. (1990). Transforming c-Ki-ras mutation is a preneoplastic event in mouse mammary carcinogenesis induced in vitro by N-methyl-N-nitrosourea. Mol Cell Biol 10: 1593-9.
48. Olivier, M., Eeles, R., et al. (2002). The IARC TP53 database: new online mutation analysis and recommendations to users. Hum Mutat 19: 607-14.
49. Osborne, M.R., Beland, F.A., et al. (1976). The reaction of (±)-7a,8b-dihydroxy-9b,10b-epoxy-7,8,9,10-tetrahydrobenzo[a]pyrene with DNA. Int J Cancer 18: 362-8.
50. Oudejans, J.J., Slebos, R.J., et al. (1991). Differential activation of ras genes by point mutation in human colon cancer with metastases to either lung or liver. Int J Cancer 49: 875-9.
51. Park, J.H., Gelhaus, S., et al. (2008a). The pattern of p53 mutations caused by PAH o-quinones is driven by 8-oxo-dGuo formation while the spectrum of mutations is determined by biological selection for dominance. Chem Res Toxicol 21: 1039-49.
52. Park, J.H., Mangal, D., et al. (2008b). Evidence for the aldo-keto reductase pathway of polycyclic aromatic trans-dihydrodiol activation in human lung A549 cells. Proc Natl Acad Sci USA 105: 6846-51.
53. Penning, T.M., Burczynski, M.E., et al. (1999). Dihydrodiol dehydrogenases and polycyclic aromatic hydrocarbon activation: generation of reactive and redox active o-quinones. Chem Res Toxicol 12: 1-18.
54. Puisieux, A., Lim, S., et al. (1991). Selective targeting of p53 gene mutational hotspots in human cancers by etiologically defined carcinogens. Cancer Res 51: 6185-9.
55. Quinlan, M.P., Quatela, S.E., et al. (2008). Activated Kras, but not Hras or Nras, may initiate tumors of endodermal origin via stem cell expansion. Mol Cell Biol 28: 2659-74.
56. Rajalingam, K., Schreck, R., et al. (2007). Ras oncogenes and their downstream targets. Biochim Biophys Acta 1773: 1177-95.
57. Reddy, E.P., Reynolds, R.K., et al. (1982). A point mutation is responsible for the acquisition of transforming properties by the T24 human bladder carcinoma oncogene. Nature 300: 149-52.
58. Reynolds, S.H., Stowers, S.J., et al. (1987). Activated oncogenes in B6C3F1 mouse liver tumors: implications for risk assessment. Science 237: 1309-16.
59. Rodenhuis, S. (1992). ras and human tumors. Semin Cancer Biol 3: 241-7.
60. Rodin, S.N. and Rodin, A.S. (2000). Human lung cancer and p53: the interplay between mutagenesis and selection. Proc Natl Acad Sci USA 97: 12244-9.
61. Rodin, S.N. and Rodin, A.S. (2002). On the origin of p53 G:C--> T:A transversions in lung cancers. Mutat Res 508: 1-19.
62. Rodin, S.N. and Rodin, A.S. (2005). Origins and selection of p53 mutations in lung carcinogenesis. Semin Cancer Biol 15: 103-112.
63. Rodin, S.N., Rodin, A.S., et al. (2002). Cancerous hyper-mutagenesis in p53 genes is possibly associated with transcriptional bypass of DNA lesions. Mutat Res 510: 153-68.
64. Rodriguez, H., Akman, S.A., et al. (2000). Mapping oxidative DNA damage using ligationmediated polymerase chain reaction technology. Methods 22: 148-56.
65. Ronai, Z.A., Gradia, S., et al. (1993). G to A transitions and G to T transversions in codon 12 of the Ki-ras oncogene isolated from mouse lung tumors induced by 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) and related DNA methylating and pyridyloxobutylating agents. Carcinogenesis 14: 2419-22.
66. Saranath, D., Chang, S.E., et al. (1991). High frequency mutation in codons 12 and 61 of H-ras oncogene in chewing tobacco-related human oral carcinoma in India. Br J Cancer 63: 573-8.
67. Shen, Y.M., Troxel, A.B., et al. (2006). Comparison of p53 mutations induced by PAH o-quinones with those caused by anti-benzo[a]pyrene diol epoxide in vitro: role of reactive oxygen and biological selection. Chem Res Toxicol 19: 1441-50.
68. Shimada, T., Hayes, C.L., et al. (1996). Activation of chemically diverse procarcinogens by human cytochrome P450 1B1. Cancer Res 56: 2979-84.
69. Smela, M.E., Currier, S.S., et al. (2001). The chemistry and biology of aflatoxin B(1): from mutational spectrometry to carcinogenesis. Carcinogenesis 22: 535-45.
70. Sukumar, S., Notario, V., et al. (1983). Induction of mammary carcinomas in rats by nitrosomethylurea involves malignant activation of H-ras-1 locus by single point mutations. Nature 306: 658-61.
71. Sutter, T.R., Tang, Y.M., et al. (1994). cDNA sequence of a human dioxin-inducible mRNA identifies a new gene subfamily of cytochrome P450 that maps to chromosome 2. J Biol Chem 269: 13092-9.
72. Tabin, C.J., Bradley, S.M., et al. (1982). Mechanism of activation of a human oncogene. Nature 300: 143-9.
73. Taparowsky, E., Suard, Y., et al. (1982). Activation of the T24 bladder carcinoma transforming gene is linked to a single amino acid change. Nature 300: 762-5.
74. To, M.D., Wong, C.E., et al. (2008). Kras regulatory elements and exon 4A determine mutation specificity in lung cancer. Nat Genet 40: 1240-4.
75. Toyooka, S., Tsuda, T., et al. (2003). The TP53 gene, tobacco exposure, and lung cancer. Hum Mutat 21: 229-39.
76. Tretyakova, N., Matter, B., et al. (2002). Formation of benzo[a]pyrene diol epoxide-DNA adducts at specific guanines within K-ras and p53 gene sequences: stable isotope-labeling mass spectrometry approach. Biochemistry 41: 9535-44.
77. Wei, S.J., Chang, R.L., et al. (1993). Dose-dependent differences in the profile of mutations induced by (+)-7R,8S-dihydroxy-9S,10R-epoxy-7,8,9,10-tetrahydrobenzo(a)pyrene in the coding region of the hypoxanthine (guanine) phosphoribosyltransferase gene in Chinese hamster V-79 cells. Cancer Res 53: 3294-301.
78. Xie, Z., Braithwaite, E., et al. (2003). Mutagenesis of benzo[a]pyrene diol-epoxide in yeast: requirement for DNA polymerase x and involvement of DNA polmerase h. Biochemistry 42: 11253-62.
79. Yoon, J.H., Lee, C.S., et al. (2003). Simulated sunlight and benzo[a]pyrene diol epoxide induced mutagenesis in the human p53 gene evaluated by the yeast functional assay: lack of correspondence to tumor mutation spectra. Carcinogenesis 24: 113-9.
80. You, M., Candrian, U., et al. (1989). Activation of the Ki-ras protooncogene in spontaneously occurring and chemically induced lung tumors of the strain A mouse. Proc Natl Acad Sci USA 86: 3070-4.
81. Yu, D., Berlin, J.A., et al. (2002). Reactive oxygen species generated by PAH o-quinones cause change-in-function mutations in p53. Chem Res Toxicol 15: 832-42.
82. Zarbl, H., Sukumar, S., et al. (1985). Direct mutagenesis of Ha-ras-1 oncogenes by N-nitroso-Nmethylurea during initiation of mammary carcinogenesis in rats. Nature 315: 382-5.